5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.85▼ | 1.85▼ | 1.85▼ | 1.78▲ | 1.88▼ |
MA10 | 1.87▼ | 1.86▼ | 1.86▼ | 1.81▼ | 2.05▼ |
MA20 | 2.00▼ | 2.02▼ | 2.02▼ | 1.86▼ | 2.17▼ |
MA50 | 2.12▼ | 2.13▼ | 2.12▼ | 2.04▼ | 2.32▼ |
MA100 | 2.23▼ | 2.25▼ | 2.27▼ | 2.19▼ | 2.52▼ |
MA200 | 2.43▼ | 2.43▼ | 2.49▼ | 2.39▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.015▼ | -0.020▼ | -0.020▼ | 0.002▲ | -0.045▼ |
RSI | 28.748▼ | 29.036▼ | 30.042▼ | 38.815▼ | 37.714▼ |
STOCH | 23.784 | 23.636 | 23.636 | 28.875 | 18.145▼ |
WILL %R | -100.000▼ | -100.000▼ | -100.000▼ | -68.182 | -91.967▼ |
CCI | -117.040▼ | -102.138▼ | -102.138▼ | -88.031 | -141.003▼ |
Monday, July 21, 2025 07:10 AM
(NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived ...
|
Monday, July 21, 2025 12:00 AM
SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Further to our announcement filed on Form 6-K on November 20, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a ...
|
Thursday, June 26, 2025 05:00 PM
The S&P 500 and Nasdaq Composite both notched new record highs shortly after Friday's open, capping a dizzying rally from the depths of April's tariff-induced selloff. The broad S&P 500 topped ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
15/08/25 | 1.74 | 1.80 | 1.74 | 1.80 | 6,384 |
14/08/25 | 1.75 | 1.784 | 1.75 | 1.784 | 1,305 |
13/08/25 | 1.75 | 1.78 | 1.73 | 1.75 | 18,910 |
12/08/25 | 1.81 | 1.83 | 1.76 | 1.77 | 18,987 |
11/08/25 | 1.84 | 1.84 | 1.7962 | 1.80 | 8,510 |
08/08/25 | 1.87 | 1.8784 | 1.85 | 1.87 | 3,266 |
07/08/25 | 1.86 | 1.86 | 1.86 | 1.86 | 326 |
06/08/25 | 1.86 | 1.86 | 1.8103 | 1.84 | 2,962 |
05/08/25 | 1.85 | 1.85 | 1.785 | 1.80 | 12,681 |
04/08/25 | 1.83 | 1.89 | 1.83 | 1.86 | 6,126 |
|
|
||||
|
|
||||
|
|